Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 4/2015

01.11.2015

Heart failure and pulmonary arteriovenous malformations in a patient with hereditary hemorrhagic telangiectasia type 2

verfasst von: Juan Du, Yan Zhu, Yu-Lin Zhang, Sha Li, Jing Huang, Xiao-Hua Luo, Lin Liu

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal-dominantly inherited vascular-malformation syndrome associated with gene mutations including ENG, ACVRL1 and SMAD4 gene. Clinically indistinguishable HHT1 and HHT2 are caused by mutations in ENG and ACVRL1 gene, respectively. Generally, pulmonary arteriovenous malformations (PAVMs) and pulmonary arterial hypertension (PAH) are rare manifestations of HHT related to ACVRL1 gene mutations. We described a female patient with HHT2 whose clinical features included epistaxis, mucocutaneous telangiectases, systemic AVMs and PAH. She also suffered from severe iron deficiency anemia and recurrent heart failure. A genetic mutation analysis disclosed a missense mutation in exon 7 of ACVRL1 gene in this patient and her daughter. A nonsense mutation in exon 7 of ACVRL1 gene was detected in her brother and her niece. This case supports that PAVMs and PAH can be rare manifestations of HHT2 patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Plauchu H, de Chadarevian JP, Bideau A, Robert JM (1989) Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 32(3):291–297CrossRefPubMed Plauchu H, de Chadarevian JP, Bideau A, Robert JM (1989) Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 32(3):291–297CrossRefPubMed
2.
Zurück zum Zitat Marchuk DA, Guttmacher AE, Penner JA, Ganguly P (1998) Report on the workshop on hereditary hemorrhagic telangiectasia, July 10–1, 19971. Am J Med Genet 76(3):269–273CrossRefPubMed Marchuk DA, Guttmacher AE, Penner JA, Ganguly P (1998) Report on the workshop on hereditary hemorrhagic telangiectasia, July 10–1, 19971. Am J Med Genet 76(3):269–273CrossRefPubMed
3.
Zurück zum Zitat McAllister KA, Grogg KM, Johnson DW et al (1994) Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8(4):345–351CrossRefPubMed McAllister KA, Grogg KM, Johnson DW et al (1994) Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8(4):345–351CrossRefPubMed
4.
Zurück zum Zitat Johnson DW, Berg JN, Gallione CJ et al (1995) A second locus for hereditary hemorrhagic telangiectasia maps to chromosome 12. Genome Res 5(1):21–28CrossRefPubMed Johnson DW, Berg JN, Gallione CJ et al (1995) A second locus for hereditary hemorrhagic telangiectasia maps to chromosome 12. Genome Res 5(1):21–28CrossRefPubMed
5.
Zurück zum Zitat Gallione CJ, Repetto GM, Legius E et al (2004) A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 363(9412):852–859CrossRefPubMed Gallione CJ, Repetto GM, Legius E et al (2004) A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 363(9412):852–859CrossRefPubMed
6.
Zurück zum Zitat Richards-Yutz J, Grant K, Chao EC, Walther SE, Ganguly A (2010) Update on molecular diagnosis of hereditary hemorrhagic telangiectasia. Hum Genet 128(1):61–77CrossRefPubMed Richards-Yutz J, Grant K, Chao EC, Walther SE, Ganguly A (2010) Update on molecular diagnosis of hereditary hemorrhagic telangiectasia. Hum Genet 128(1):61–77CrossRefPubMed
7.
Zurück zum Zitat Prigoda NL, Savas S, Abdalla SA et al (2006) Hereditary haemorrhagic telangiectasia: mutation detection, test sensitivity and novel mutations. J Med Genet 43(9):722–728PubMedCentralCrossRefPubMed Prigoda NL, Savas S, Abdalla SA et al (2006) Hereditary haemorrhagic telangiectasia: mutation detection, test sensitivity and novel mutations. J Med Genet 43(9):722–728PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Cole SG, Begbie ME, Wallace GM, Shovlin CL (2005) A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet 42(7):577–582PubMedCentralCrossRefPubMed Cole SG, Begbie ME, Wallace GM, Shovlin CL (2005) A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet 42(7):577–582PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Bayrak-Toydemir P, McDonald J, Akarsu N, Toydemir RM, Calderon F, Tuncali T, Tang W, Miller F, Mao R (2006) A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am J Med Genet A 140(20):2155–2162CrossRefPubMed Bayrak-Toydemir P, McDonald J, Akarsu N, Toydemir RM, Calderon F, Tuncali T, Tang W, Miller F, Mao R (2006) A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am J Med Genet A 140(20):2155–2162CrossRefPubMed
10.
Zurück zum Zitat David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S (2007) Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 109(5):1953–1961CrossRefPubMed David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S (2007) Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 109(5):1953–1961CrossRefPubMed
11.
Zurück zum Zitat Castonguay R, Werner ED, Matthews RG et al (2011) Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth. J Biol Chem 286(34):30034–30046PubMedCentralCrossRefPubMed Castonguay R, Werner ED, Matthews RG et al (2011) Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth. J Biol Chem 286(34):30034–30046PubMedCentralCrossRefPubMed
12.
Zurück zum Zitat Tillet E, Bailly S (2014) Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia. Front Genet 5:456PubMedCentralPubMed Tillet E, Bailly S (2014) Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia. Front Genet 5:456PubMedCentralPubMed
13.
Zurück zum Zitat Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, Kjeldsen AD, Plauchu H (2000) Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 91(1):66–67CrossRefPubMed Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, Kjeldsen AD, Plauchu H (2000) Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 91(1):66–67CrossRefPubMed
14.
Zurück zum Zitat Pasculli G, Resta F, Guastamacchia E, Di Gennaro L, Suppressa P, Sabba C (2004) Health-related quality of life in a rare disease: hereditary hemorrhagic telangiectasia (HHT) or Rendu-Osler-Weber disease. Qual Life Res 13(10):1715–1723CrossRefPubMed Pasculli G, Resta F, Guastamacchia E, Di Gennaro L, Suppressa P, Sabba C (2004) Health-related quality of life in a rare disease: hereditary hemorrhagic telangiectasia (HHT) or Rendu-Osler-Weber disease. Qual Life Res 13(10):1715–1723CrossRefPubMed
15.
Zurück zum Zitat Faughnan ME, Palda VA, Garcia-Tsao G et al (2011) International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 48(2):73–87CrossRefPubMed Faughnan ME, Palda VA, Garcia-Tsao G et al (2011) International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 48(2):73–87CrossRefPubMed
16.
Zurück zum Zitat Stross P (2013) Woman presenting with chronic iron deficiency anemia associated with hereditary hemorrhagic telangiectasia: a case report. Drug Healthc Patient Saf 5:203–210PubMedCentralCrossRefPubMed Stross P (2013) Woman presenting with chronic iron deficiency anemia associated with hereditary hemorrhagic telangiectasia: a case report. Drug Healthc Patient Saf 5:203–210PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Letteboer TG, Mager JJ, Snijder RJ, Koeleman BP, Lindhout D, Ploos van Amstel JK, Westermann CJ (2006) Genotype-phenotype relationship in hereditary haemorrhagic telangiectasia. J Med Genet 43(4):371–377PubMedCentralCrossRefPubMed Letteboer TG, Mager JJ, Snijder RJ, Koeleman BP, Lindhout D, Ploos van Amstel JK, Westermann CJ (2006) Genotype-phenotype relationship in hereditary haemorrhagic telangiectasia. J Med Genet 43(4):371–377PubMedCentralCrossRefPubMed
18.
Zurück zum Zitat Mahmoud M, Borthwick GM, Hislop AA, Arthur HM (2009) Endoglin and activin receptor-like-kinase 1 are co-expressed in the distal vessels of the lung: implications for two familial vascular dysplasias, HHT and PAH. Lab Investig 89(1):15–25CrossRefPubMed Mahmoud M, Borthwick GM, Hislop AA, Arthur HM (2009) Endoglin and activin receptor-like-kinase 1 are co-expressed in the distal vessels of the lung: implications for two familial vascular dysplasias, HHT and PAH. Lab Investig 89(1):15–25CrossRefPubMed
19.
Zurück zum Zitat Gossage JR, Kanj G (1998) Pulmonary arteriovenous malformations: a state of the art review. Am J Respir Crit Care Med 158(2):643–661CrossRefPubMed Gossage JR, Kanj G (1998) Pulmonary arteriovenous malformations: a state of the art review. Am J Respir Crit Care Med 158(2):643–661CrossRefPubMed
20.
Zurück zum Zitat Moyer JH, Glantz G, Brest AN (1962) Pulmonary arteriovenous fistulas: physiologic and clinical considerations. Am J Med 32:417–435CrossRefPubMed Moyer JH, Glantz G, Brest AN (1962) Pulmonary arteriovenous fistulas: physiologic and clinical considerations. Am J Med 32:417–435CrossRefPubMed
21.
Zurück zum Zitat Rodan BA, Goodwin JD, Chen JT, Ravin CE (1981) Worsening pulmonary hypertension after resection of arteriovenous fistula. AJR Am J Roentgenol 137(4):864–866CrossRefPubMed Rodan BA, Goodwin JD, Chen JT, Ravin CE (1981) Worsening pulmonary hypertension after resection of arteriovenous fistula. AJR Am J Roentgenol 137(4):864–866CrossRefPubMed
22.
Zurück zum Zitat Cottin V, Dupuis-Girod S, Lesca G, Cordier JF (2007) Pulmonary vascular manifestations of hereditary hemorrhagic telangiectasia (Rendu-Osler disease). Respiration 74(4):361–378CrossRefPubMed Cottin V, Dupuis-Girod S, Lesca G, Cordier JF (2007) Pulmonary vascular manifestations of hereditary hemorrhagic telangiectasia (Rendu-Osler disease). Respiration 74(4):361–378CrossRefPubMed
23.
Zurück zum Zitat Trembath RC, Thomson JR, Machado RD et al (2001) Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 345(5):325–334CrossRefPubMed Trembath RC, Thomson JR, Machado RD et al (2001) Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 345(5):325–334CrossRefPubMed
24.
Zurück zum Zitat Harrison RE, Flanagan JA, Sankelo M et al (2003) Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet 40(12):865–871PubMedCentralCrossRefPubMed Harrison RE, Flanagan JA, Sankelo M et al (2003) Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet 40(12):865–871PubMedCentralCrossRefPubMed
26.
Zurück zum Zitat Girerd B, Montani D, Coulet F et al (2010) Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med 181(8):851–861CrossRefPubMed Girerd B, Montani D, Coulet F et al (2010) Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med 181(8):851–861CrossRefPubMed
Metadaten
Titel
Heart failure and pulmonary arteriovenous malformations in a patient with hereditary hemorrhagic telangiectasia type 2
verfasst von
Juan Du
Yan Zhu
Yu-Lin Zhang
Sha Li
Jing Huang
Xiao-Hua Luo
Lin Liu
Publikationsdatum
01.11.2015
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 4/2015
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-015-1253-z

Weitere Artikel der Ausgabe 4/2015

Journal of Thrombosis and Thrombolysis 4/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.